Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 1.6% on Tuesday . The company traded as low as $5.72 and last traded at $5.75. 2,857,604 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 12,252,407 shares. The stock had previously closed at $5.84.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus price target of $8.20.

Recursion Pharmaceuticals Price Performance

The stock has a 50-day simple moving average of $5.82 and a 200 day simple moving average of $6.74. The company has a market cap of $2.29 billion, a PE ratio of -3.73 and a beta of 1.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The firm's quarterly revenue was down 57.8% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth $99,152,000. Novo Holdings A S acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth about $68,375,000. Vanguard Group Inc. grew its position in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $23,429,000. Finally, Laurion Capital Management LP purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $16,611,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.